JP2007502124A - 改良ケトレダクターゼポリペプチドおよび関連ポリヌクレオチド - Google Patents
改良ケトレダクターゼポリペプチドおよび関連ポリヌクレオチド Download PDFInfo
- Publication number
- JP2007502124A JP2007502124A JP2006523448A JP2006523448A JP2007502124A JP 2007502124 A JP2007502124 A JP 2007502124A JP 2006523448 A JP2006523448 A JP 2006523448A JP 2006523448 A JP2006523448 A JP 2006523448A JP 2007502124 A JP2007502124 A JP 2007502124A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- kred
- polypeptide
- sequence
- kred polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001110310 Lentilactobacillus kefiri NADP-dependent (R)-specific alcohol dehydrogenase Proteins 0.000 title claims abstract description 316
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 263
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 258
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 258
- 102000040430 polynucleotide Human genes 0.000 title claims abstract description 95
- 108091033319 polynucleotide Proteins 0.000 title claims abstract description 95
- 239000002157 polynucleotide Substances 0.000 title claims abstract description 95
- 230000000694 effects Effects 0.000 claims abstract description 108
- 230000014509 gene expression Effects 0.000 claims abstract description 45
- 239000013598 vector Substances 0.000 claims abstract description 36
- 239000002773 nucleotide Substances 0.000 claims abstract description 15
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 74
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 60
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 54
- 150000007523 nucleic acids Chemical group 0.000 claims description 52
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 25
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 22
- 238000006467 substitution reaction Methods 0.000 claims description 20
- 125000000539 amino acid group Chemical group 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 230000001105 regulatory effect Effects 0.000 claims description 14
- 230000036961 partial effect Effects 0.000 claims description 12
- 238000012217 deletion Methods 0.000 claims description 10
- 230000037430 deletion Effects 0.000 claims description 10
- 238000003780 insertion Methods 0.000 claims description 8
- 230000037431 insertion Effects 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 6
- 238000011534 incubation Methods 0.000 claims description 5
- 101000611441 Solanum lycopersicum Pathogenesis-related leaf protein 6 Proteins 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 102200072983 rs1630312 Human genes 0.000 claims description 4
- 102220587867 Acidic mammalian chitinase_S22T_mutation Human genes 0.000 claims description 3
- 101100462457 African swine fever virus (strain Badajoz 1971 Vero-adapted) Ba71V-049 gene Proteins 0.000 claims description 3
- 102220534433 Carbonic anhydrase 1_S66G_mutation Human genes 0.000 claims description 3
- 102220584188 Cellular tumor antigen p53_A86V_mutation Human genes 0.000 claims description 3
- 102220468645 HLA class II histocompatibility antigen, DP beta 1 chain_K98R_mutation Human genes 0.000 claims description 3
- 102220632167 Histone-lysine N-trimethyltransferase SMYD5_N65Y_mutation Human genes 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 102200075063 rs104894696 Human genes 0.000 claims description 3
- 102220215481 rs1060501504 Human genes 0.000 claims description 3
- 102220226091 rs1064794928 Human genes 0.000 claims description 3
- 102200017268 rs121918392 Human genes 0.000 claims description 3
- 102200071151 rs137853184 Human genes 0.000 claims description 3
- 102220316985 rs1553640288 Human genes 0.000 claims description 3
- 102220075807 rs202025584 Human genes 0.000 claims description 3
- 102200118232 rs33959340 Human genes 0.000 claims description 3
- 102220005322 rs33959340 Human genes 0.000 claims description 3
- 102200082890 rs33972047 Human genes 0.000 claims description 3
- 102200118227 rs34579351 Human genes 0.000 claims description 3
- 102220005528 rs34814612 Human genes 0.000 claims description 3
- 102220071199 rs376603102 Human genes 0.000 claims description 3
- 102220005354 rs63749934 Human genes 0.000 claims description 3
- 102220201926 rs764396688 Human genes 0.000 claims description 3
- 102220277697 rs773347338 Human genes 0.000 claims description 3
- 102200063469 rs869312823 Human genes 0.000 claims description 3
- 102220103310 rs878854070 Human genes 0.000 claims description 3
- 102220160611 rs886048391 Human genes 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 2
- 239000004295 calcium sulphite Substances 0.000 claims 2
- 102220533209 Baculoviral IAP repeat-containing protein 5_K79R_mutation Human genes 0.000 claims 1
- 102220591051 Cellular tumor antigen p53_T18A_mutation Human genes 0.000 claims 1
- 102220503704 Cyclin-dependent kinase 8_V27L_mutation Human genes 0.000 claims 1
- 102220624314 Interferon alpha-8_N65D_mutation Human genes 0.000 claims 1
- 102220599171 Leukocyte cell-derived chemotaxin-2_H67L_mutation Human genes 0.000 claims 1
- 102220594800 Sequestosome-1_A16V_mutation Human genes 0.000 claims 1
- 102220353591 c.16A>G Human genes 0.000 claims 1
- 102220351976 c.268A>G Human genes 0.000 claims 1
- 102200046175 rs104894187 Human genes 0.000 claims 1
- 102200098368 rs137852607 Human genes 0.000 claims 1
- 102220274086 rs1379627026 Human genes 0.000 claims 1
- 102200088301 rs2287555 Human genes 0.000 claims 1
- 102200082872 rs34866629 Human genes 0.000 claims 1
- 102200120197 rs690016544 Human genes 0.000 claims 1
- 102220213921 rs762028131 Human genes 0.000 claims 1
- 102220082365 rs863224257 Human genes 0.000 claims 1
- 230000009467 reduction Effects 0.000 abstract description 17
- 150000002576 ketones Chemical class 0.000 abstract description 15
- 230000000707 stereoselective effect Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 97
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 50
- 108090000623 proteins and genes Proteins 0.000 description 50
- 238000000034 method Methods 0.000 description 46
- 235000001014 amino acid Nutrition 0.000 description 32
- 102000004190 Enzymes Human genes 0.000 description 29
- 108090000790 Enzymes Proteins 0.000 description 29
- 229940088598 enzyme Drugs 0.000 description 29
- 108091026890 Coding region Proteins 0.000 description 28
- 239000013604 expression vector Substances 0.000 description 28
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 27
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 21
- 108020004705 Codon Proteins 0.000 description 20
- 241000588724 Escherichia coli Species 0.000 description 20
- 102000039446 nucleic acids Human genes 0.000 description 20
- 108020004707 nucleic acids Proteins 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 18
- 239000011159 matrix material Substances 0.000 description 18
- 108010076504 Protein Sorting Signals Proteins 0.000 description 17
- 238000006722 reduction reaction Methods 0.000 description 17
- 239000006166 lysate Substances 0.000 description 16
- 230000035772 mutation Effects 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 230000010076 replication Effects 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 230000007423 decrease Effects 0.000 description 13
- 238000012216 screening Methods 0.000 description 13
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 12
- 230000008929 regeneration Effects 0.000 description 12
- 238000011069 regeneration method Methods 0.000 description 12
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 11
- 229960005091 chloramphenicol Drugs 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 238000007429 general method Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 240000006439 Aspergillus oryzae Species 0.000 description 8
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 8
- -1 cyano-3-hydroxybutyric acid ester Chemical class 0.000 description 8
- 230000010354 integration Effects 0.000 description 8
- 239000004382 Amylase Substances 0.000 description 7
- 108010065511 Amylases Proteins 0.000 description 7
- 102000013142 Amylases Human genes 0.000 description 7
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 7
- 235000019418 amylase Nutrition 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 229950006238 nadide Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 101000755953 Bacillus subtilis (strain 168) Ribosome maturation factor RimP Proteins 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 241000222292 [Candida] magnoliae Species 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 230000002538 fungal effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 230000008488 polyadenylation Effects 0.000 description 6
- 102220277134 rs776745497 Human genes 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 5
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 108090000637 alpha-Amylases Proteins 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 241000228212 Aspergillus Species 0.000 description 4
- 241000351920 Aspergillus nidulans Species 0.000 description 4
- 241000228245 Aspergillus niger Species 0.000 description 4
- 101000757144 Aspergillus niger Glucoamylase Proteins 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 102000004139 alpha-Amylases Human genes 0.000 description 4
- 229940024171 alpha-amylase Drugs 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 101150109249 lacI gene Proteins 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical class CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 3
- 108010037870 Anthranilate Synthase Proteins 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 3
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 3
- 108090000204 Dipeptidase 1 Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 108010048241 acetamidase Proteins 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000174 gluconic acid Substances 0.000 description 3
- 235000012208 gluconic acid Nutrition 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 238000011946 reduction process Methods 0.000 description 3
- 102220242548 rs750080180 Human genes 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108010031132 Alcohol Oxidoreductases Proteins 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 101100163849 Arabidopsis thaliana ARS1 gene Proteins 0.000 description 2
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 2
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 2
- 102220597216 Cytoplasmic FMR1-interacting protein 1_N16D_mutation Human genes 0.000 description 2
- 102220526130 Dihydrofolate reductase_N65S_mutation Human genes 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 108090000698 Formate Dehydrogenases Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102220480531 GSK3B-interacting protein_K85R_mutation Human genes 0.000 description 2
- 102000048120 Galactokinases Human genes 0.000 description 2
- 108700023157 Galactokinases Proteins 0.000 description 2
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 102220624447 Iron-sulfur cluster assembly enzyme ISCU, mitochondrial_N90D_mutation Human genes 0.000 description 2
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000235403 Rhizomucor miehei Species 0.000 description 2
- 101100097319 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ala1 gene Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 2
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 102220470569 Tryptase delta_K79R_mutation Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 230000002210 biocatalytic effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 102220353333 c.35C>T Human genes 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 2
- OHLRLMWUFVDREV-UHFFFAOYSA-N ethyl 4-chloro-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)CCl OHLRLMWUFVDREV-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 108010061330 glucan 1,4-alpha-maltohydrolase Proteins 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 101150054232 pyrG gene Proteins 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 102200042490 rs137853008 Human genes 0.000 description 2
- 102220028864 rs145479679 Human genes 0.000 description 2
- 102220278884 rs1554569658 Human genes 0.000 description 2
- 102220283130 rs1555750818 Human genes 0.000 description 2
- 102200080116 rs556297791 Human genes 0.000 description 2
- 102220037054 rs587780188 Human genes 0.000 description 2
- 102220045277 rs587781972 Human genes 0.000 description 2
- 102200001739 rs72552725 Human genes 0.000 description 2
- 102220277695 rs876658941 Human genes 0.000 description 2
- 102220185661 rs886052388 Human genes 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- JKTYIIAAAZPIFQ-UHFFFAOYSA-N 2-phenylbenzenesulfonyl fluoride Chemical compound FS(=O)(=O)C1=CC=CC=C1C1=CC=CC=C1 JKTYIIAAAZPIFQ-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 1
- WGNSGQNASYNCBU-UHFFFAOYSA-N 4-bromo-3-hydroxybutanoic acid Chemical compound BrCC(O)CC(O)=O WGNSGQNASYNCBU-UHFFFAOYSA-N 0.000 description 1
- ADZQCEUEGXRCJY-UHFFFAOYSA-N 4-cyano-3-hydroxybutanoic acid Chemical compound N#CCC(O)CC(O)=O ADZQCEUEGXRCJY-UHFFFAOYSA-N 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 102000005751 Alcohol Oxidoreductases Human genes 0.000 description 1
- 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 description 1
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000534414 Anotopterus nikparini Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DJHGAFSJWGLOIV-UHFFFAOYSA-K Arsenate3- Chemical compound [O-][As]([O-])([O-])=O DJHGAFSJWGLOIV-UHFFFAOYSA-K 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102000035101 Aspartic proteases Human genes 0.000 description 1
- 108091005502 Aspartic proteases Proteins 0.000 description 1
- 101000961203 Aspergillus awamori Glucoamylase Proteins 0.000 description 1
- 101000690713 Aspergillus niger Alpha-glucosidase Proteins 0.000 description 1
- 101900127796 Aspergillus oryzae Glucoamylase Proteins 0.000 description 1
- 101900318521 Aspergillus oryzae Triosephosphate isomerase Proteins 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 101000775727 Bacillus amyloliquefaciens Alpha-amylase Proteins 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 101000695691 Bacillus licheniformis Beta-lactamase Proteins 0.000 description 1
- 108010029675 Bacillus licheniformis alpha-amylase Proteins 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 101900040182 Bacillus subtilis Levansucrase Proteins 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 102100030981 Beta-alanine-activating enzyme Human genes 0.000 description 1
- 102100021973 Carbonyl reductase [NADPH] 1 Human genes 0.000 description 1
- 102220520325 Cell cycle regulator of non-homologous end joining_P14A_mutation Human genes 0.000 description 1
- 102100037633 Centrin-3 Human genes 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 101100342470 Dictyostelium discoideum pkbA gene Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101100385973 Escherichia coli (strain K12) cycA gene Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000223221 Fusarium oxysporum Species 0.000 description 1
- 101150108358 GLAA gene Proteins 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 101100001650 Geobacillus stearothermophilus amyM gene Proteins 0.000 description 1
- 101100080316 Geobacillus stearothermophilus nprT gene Proteins 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 102100035172 Glucose-6-phosphate 1-dehydrogenase Human genes 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101100295959 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) arcB gene Proteins 0.000 description 1
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000773364 Homo sapiens Beta-alanine-activating enzyme Proteins 0.000 description 1
- 101000880522 Homo sapiens Centrin-3 Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101150068888 MET3 gene Proteins 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 101100022915 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-11 gene Proteins 0.000 description 1
- 108090000913 Nitrate Reductases Proteins 0.000 description 1
- 241001306288 Ophrys fuciflora Species 0.000 description 1
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 1
- 101710113020 Ornithine transcarbamylase, mitochondrial Proteins 0.000 description 1
- 102100037214 Orotidine 5'-phosphate decarboxylase Human genes 0.000 description 1
- 108010055012 Orotidine-5'-phosphate decarboxylase Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000028391 RNA cap binding Human genes 0.000 description 1
- 108091000106 RNA cap binding Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 241000235402 Rhizomucor Species 0.000 description 1
- 101000968489 Rhizomucor miehei Lipase Proteins 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 101900354623 Saccharomyces cerevisiae Galactokinase Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 101100022918 Schizosaccharomyces pombe (strain 972 / ATCC 24843) sua1 gene Proteins 0.000 description 1
- 102100032491 Serine protease 1 Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101100309436 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) ftf gene Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000187432 Streptomyces coelicolor Species 0.000 description 1
- 101100370749 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) trpC1 gene Proteins 0.000 description 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 101150050575 URA3 gene Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010045649 agarase Proteins 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 101150009206 aprE gene Proteins 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 101150008194 argB gene Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940000489 arsenate Drugs 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 101150103518 bar gene Proteins 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 150000004718 beta keto acids Chemical class 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- ZQNPDAVSHFGLIQ-UHFFFAOYSA-N calcium;hydrate Chemical compound O.[Ca] ZQNPDAVSHFGLIQ-UHFFFAOYSA-N 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- GUPIFCPOAUCSQC-UHFFFAOYSA-L copper;sulfate;tetrahydrate Chemical compound O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O GUPIFCPOAUCSQC-UHFFFAOYSA-L 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 101150005799 dagA gene Proteins 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 125000000950 dibromo group Chemical group Br* 0.000 description 1
- XQGPKZUNMMFTAL-UHFFFAOYSA-L dipotassium;hydrogen phosphate;trihydrate Chemical compound O.O.O.[K+].[K+].OP([O-])([O-])=O XQGPKZUNMMFTAL-UHFFFAOYSA-L 0.000 description 1
- CDMADVZSLOHIFP-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane;decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 CDMADVZSLOHIFP-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- ZAJNMXDBJKCCAT-YFKPBYRVSA-N ethyl (3s)-4-chloro-3-hydroxybutanoate Chemical compound CCOC(=O)C[C@H](O)CCl ZAJNMXDBJKCCAT-YFKPBYRVSA-N 0.000 description 1
- AIZRKZQHJNWBEI-UHFFFAOYSA-N ethyl 4-bromo-3-hydroxybutanoate Chemical compound CCOC(=O)CC(O)CBr AIZRKZQHJNWBEI-UHFFFAOYSA-N 0.000 description 1
- ZAJNMXDBJKCCAT-UHFFFAOYSA-N ethyl 4-chloro-3-hydroxybutanoate Chemical compound CCOC(=O)CC(O)CCl ZAJNMXDBJKCCAT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 101150019455 gdh gene Proteins 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003944 halohydrins Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 108010055049 hydrogen dehydrogenase Proteins 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 108010002685 hygromycin-B kinase Proteins 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 108010084715 isopropanol dehydrogenase (NADP) Proteins 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 101150039489 lysZ gene Proteins 0.000 description 1
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000033607 mismatch repair Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 101150095344 niaD gene Proteins 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 108090000021 oryzin Proteins 0.000 description 1
- KQAOIKIZSJJTII-UHFFFAOYSA-N p-mercuribenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C([Hg])C=C1 KQAOIKIZSJJTII-UHFFFAOYSA-N 0.000 description 1
- 101150019841 penP gene Proteins 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 101150108007 prs gene Proteins 0.000 description 1
- 101150086435 prs1 gene Proteins 0.000 description 1
- 101150070305 prsA gene Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000032537 response to toxin Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- 102220207006 rs1057524249 Human genes 0.000 description 1
- 102220222124 rs1060504037 Human genes 0.000 description 1
- 102220014369 rs145665265 Human genes 0.000 description 1
- 102220062022 rs150142859 Human genes 0.000 description 1
- 102200133203 rs3218619 Human genes 0.000 description 1
- 102220049651 rs59662841 Human genes 0.000 description 1
- 102220008752 rs6667 Human genes 0.000 description 1
- 101150025220 sacB gene Proteins 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 101150016309 trpC gene Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 101150052264 xylA gene Proteins 0.000 description 1
- 101150110790 xylB gene Proteins 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49419503P | 2003-08-11 | 2003-08-11 | |
| US54568204P | 2004-02-18 | 2004-02-18 | |
| PCT/US2004/026655 WO2005017135A1 (en) | 2003-08-11 | 2004-08-11 | Improved ketoreductase polypeptides and related polynucleotides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007502124A true JP2007502124A (ja) | 2007-02-08 |
| JP2007502124A5 JP2007502124A5 (enExample) | 2007-08-02 |
Family
ID=34197992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006523448A Pending JP2007502124A (ja) | 2003-08-11 | 2004-08-11 | 改良ケトレダクターゼポリペプチドおよび関連ポリヌクレオチド |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7629157B2 (enExample) |
| EP (1) | EP1654354A1 (enExample) |
| JP (1) | JP2007502124A (enExample) |
| CA (1) | CA2533838A1 (enExample) |
| IL (1) | IL173191A (enExample) |
| WO (1) | WO2005017135A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010539952A (ja) * | 2007-10-01 | 2010-12-24 | コデクシス， インコーポレイテッド | アゼチジノンの生産のためのケトレダクターゼポリペプチド |
| WO2011145211A1 (ja) * | 2010-05-21 | 2011-11-24 | 明治製菓株式会社 | ケトレダクターゼ変異体 |
| JP2022536500A (ja) * | 2019-06-13 | 2022-08-17 | アシムケム ラボラトリーズ （ティエンジン） カンパニー リミテッド | ケトレダクターゼ突然変異体及びキラルアルコールの生産方法 |
Families Citing this family (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003258187A1 (en) | 2002-08-09 | 2004-02-25 | Codexis, Inc. | Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives |
| BRPI0413498A (pt) | 2003-08-11 | 2006-10-17 | Codexis Inc | método para produzir um éster de ácido carboxìlico substituìdo por hidróxi, ciano vicinal a partir de um éster de ácido carboxìlico substituìdo por hidróxi, halo vicinal, e, composição |
| EP1908845A4 (en) * | 2005-07-20 | 2010-10-06 | Kaneka Corp | PROCESS FOR THE PRODUCTION OF 2- (AMINOMETHYL-N-SUBSTITUTED) 3-HYDROXYBUTYRIC ACID L ESTER WITH OPTICAL ACTIVITY |
| AT502395B1 (de) | 2005-07-27 | 2007-03-15 | Iep Gmbh | Oxidoreduktasen zur stereoselektiven reduktion von ketoverbindungen |
| WO2008100251A1 (en) | 2007-02-13 | 2008-08-21 | Ls9, Inc. | Modified microorganism uses therefor |
| DE102006010994A1 (de) * | 2006-03-09 | 2007-09-13 | Wacker Chemie Ag | Verfahren zur enzymatischen Herstellung von chiralen Alkoholen |
| AT503486B1 (de) * | 2006-04-11 | 2008-05-15 | Iep Gmbh | Verfahren zur enantioselektiven reduktion von steroiden |
| US8110670B2 (en) | 2006-05-19 | 2012-02-07 | Ls9, Inc. | Enhanced production of fatty acid derivatives |
| US20100242345A1 (en) | 2006-05-19 | 2010-09-30 | LS9, Inc | Production of fatty acids & derivatives thereof |
| EP2194119A3 (en) | 2006-05-19 | 2010-09-22 | LS9, Inc. | Production of fatty acids and derivatives thereof |
| KR20090083900A (ko) | 2006-10-02 | 2009-08-04 | 코덱시스, 인코포레이티드 | 입체이성질체적으로 순수한 스타틴 및 이의 합성 중간체 제조용 조성물 및 제조 방법 |
| WO2008103248A1 (en) * | 2007-02-08 | 2008-08-28 | Codexis, Inc. | Ketoreductases and uses thereof |
| CA3035878C (en) | 2007-03-28 | 2023-01-03 | REG Life Sciences, LLC | Enhanced production of fatty acid derivatives |
| WO2009029554A2 (en) | 2007-08-24 | 2009-03-05 | Codexis, Inc. | Improved ketoreductase polypeptides for the stereoselective production of (r)-3-hydroxythiolane |
| US8748143B2 (en) | 2007-09-13 | 2014-06-10 | Codexis, Inc. | Ketoreductase polypeptides for the reduction of acetophenones |
| WO2009042984A1 (en) | 2007-09-28 | 2009-04-02 | Codexis, Inc. | Ketoreductase polypeptides and uses thereof |
| WO2009045507A2 (en) * | 2007-10-03 | 2009-04-09 | Teva Pharmaceutical Industries Ltd. | Processes for preparing an intermediate of sitagliptin via enzymatic reduction |
| EP2285948B1 (en) | 2008-03-03 | 2014-01-08 | Joule Unlimited Technologies, Inc. | Engineered co2 fixing microorganisms producing carbon-based products of interest |
| CN102066561B (zh) | 2008-06-13 | 2013-09-25 | 科德克希思公司 | 合成多核苷酸变体的方法 |
| US20090312196A1 (en) | 2008-06-13 | 2009-12-17 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
| ES2438576T3 (es) | 2008-06-24 | 2014-01-17 | Codexis, Inc. | Procesos biocatalíticos para la preparación de compuestos de prolina bicíclica fusionada considerablemente pura estereoméricamente |
| US8288131B2 (en) * | 2008-08-27 | 2012-10-16 | Codexis, Inc. | Ketoreductase polypeptides and uses thereof |
| WO2010025287A2 (en) | 2008-08-27 | 2010-03-04 | Codexis, Inc. | Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine |
| HUE026181T2 (en) | 2008-08-27 | 2016-05-30 | Codexis Inc | Ketoreductase polypeptide for the preparation of 3-aryl-3-hydroxypropanamine from 3-aryl-3-ketopropanamine |
| EP2329014B1 (en) | 2008-08-29 | 2014-10-22 | Codexis, Inc. | Ketoreductase polypeptides for the stereoselective production of (4s)-3[(5s)-5(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one |
| BRPI0914440A8 (pt) | 2008-10-17 | 2016-01-19 | Joule Unlimited Inc | Método para produção biogênica de etanol e cianobactéria geneticamente modificada |
| CN102325864B (zh) | 2008-12-23 | 2016-01-27 | Reg生命科学有限责任公司 | 硫酯酶相关的方法和组合物 |
| DK3354727T3 (da) | 2009-01-08 | 2020-11-16 | Codexis Inc | Transaminasepolypeptider |
| EP2401369B1 (en) | 2009-02-26 | 2014-12-24 | Codexis, Inc. | Beta-glucosidase variant enzymes and related polynucleotides |
| WO2010099501A2 (en) | 2009-02-26 | 2010-09-02 | Codexis, Inc. | Transaminase biocatalysts |
| US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
| WO2010107644A2 (en) | 2009-03-17 | 2010-09-23 | Codexis, Inc. | Variant endoglucanases and related polynucleotides |
| BRPI1015313B1 (pt) | 2009-04-27 | 2021-06-01 | Genomatica, Inc. | Método fermentativo para produzir um éster de ácido graxo empregando um microorganismo geneticamente modificado e método para a produção de ésteres de ácidos graxos |
| WO2010135624A2 (en) | 2009-05-22 | 2010-11-25 | Codexis, Inc. | Engineered biosynthesis of fatty alcohols |
| EP2446026B1 (en) | 2009-06-22 | 2017-08-09 | Codexis, Inc. | Transaminase reactions |
| DK3409765T3 (da) | 2009-06-22 | 2021-09-27 | Codexis Inc | Ketoreduktase-medieret stereoselektiv rute til alpha-chloralkoholer |
| CN102471781B (zh) | 2009-06-30 | 2015-03-18 | 科德克希思公司 | 以脂肪醇形成酰基CoA还原酶(FAR)产生脂肪醇 |
| ES2575560T3 (es) | 2009-08-19 | 2016-06-29 | Codexis, Inc. | Polipéptidos cetorreductasa para preparar fenilefrina |
| DK2478137T3 (da) | 2009-09-18 | 2017-11-27 | Codexis Inc | Reduceret kodonmutagenese |
| US20110082055A1 (en) * | 2009-09-18 | 2011-04-07 | Codexis, Inc. | Reduced codon mutagenesis |
| US8895271B2 (en) | 2009-12-08 | 2014-11-25 | Codexis, Inc. | Synthesis of prazole compounds |
| US8715962B2 (en) | 2010-03-31 | 2014-05-06 | Codexis, Inc. | Production of geranyl diphosphate |
| WO2011140219A1 (en) | 2010-05-04 | 2011-11-10 | Codexis, Inc. | Biocatalysts for ezetimibe synthesis |
| HUE038434T2 (hu) * | 2010-06-17 | 2018-10-29 | Codexis Inc | Biokatalizátorok és módszerek (S)-3(1-aminoetil)-fenol szintéziséhez |
| US8574878B2 (en) | 2010-06-28 | 2013-11-05 | Behnaz Behrouzian | Fatty alcohol forming acyl reductases (FARs) and methods of use thereof |
| WO2012024100A2 (en) | 2010-08-16 | 2012-02-23 | Merck Sharp & Dohme Corp. | Process for preparing aminocyclohexyl ether compounds |
| EP2606139B1 (en) | 2010-08-16 | 2015-07-15 | Codexis, Inc. | Biocatalysts and methods for the synthesis of (1r,2r)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine |
| US9322027B2 (en) | 2010-08-20 | 2016-04-26 | Shell Oil Company | Expression constructs comprising fungal promoters |
| WO2012031072A1 (en) | 2010-09-01 | 2012-03-08 | Concert Pharmaceuticals, Inc. | Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation |
| WO2012031073A1 (en) * | 2010-09-01 | 2012-03-08 | Concert Pharmaceuticals, Inc. | Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation |
| JP5933557B2 (ja) * | 2010-09-14 | 2016-06-15 | カウンスル オブ サイエンティフィック アンド インダストリアル リサーチ | 高流束中空繊維限外濾過膜及びその調製方法 |
| WO2012046254A2 (en) * | 2010-10-08 | 2012-04-12 | Cadila Healthcare Limited | Process for preparing an intermediate of sitagliptin via enzymatic conversion |
| EP2649187B1 (en) | 2010-12-08 | 2017-11-22 | Codexis, Inc. | Biocatalysts and methods for the synthesis of armodafinil |
| HUE038800T2 (hu) | 2011-04-13 | 2018-11-28 | Codexis Inc | Biokatalitikus eljárás eszlikarbazepin és ennek analógjai elõállítására |
| EP2726651B1 (en) | 2011-06-28 | 2018-11-07 | Codexis, Inc. | Protein variant generation by region shuffling |
| US9109209B2 (en) | 2011-09-08 | 2015-08-18 | Codexis, Inc. | Biocatalysts and methods for the synthesis of substituted lactams |
| KR20140091700A (ko) | 2011-10-19 | 2014-07-22 | 시플라 리미티드 | 엔도텔린 수용체 길항제의 제조방법 |
| WO2013074650A1 (en) | 2011-11-18 | 2013-05-23 | Codexis, Inc. | Biocatalysts for the preparation of hydroxy substituted carbamates |
| EP2794893A4 (en) | 2011-12-20 | 2015-08-12 | Codexis Inc | PRODUCTION OF SATURATED FATTY ALCOHOLS FROM GENETICALLY MODIFIED MICROORGANISMS |
| US9139821B2 (en) | 2012-03-23 | 2015-09-22 | Codexis, Inc. | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs |
| HRP20191632T1 (hr) | 2012-03-23 | 2019-12-13 | Novartis Ag | Kemijski postupak dobivanja spiroindolona i njihovih međuprodukata |
| US20150133698A1 (en) | 2012-04-20 | 2015-05-14 | Codexis, Inc. | Production of fatty alcohols from engineered microorganisms |
| CN104428412B (zh) | 2012-05-08 | 2017-09-08 | 科德克希思公司 | 用于化合物的羟基化的生物催化剂和方法 |
| CN107904216B (zh) | 2012-05-11 | 2021-06-29 | 科德克希思公司 | 工程化亚胺还原酶以及用于酮和胺化合物的还原胺化的方法 |
| US9650655B2 (en) | 2012-07-20 | 2017-05-16 | Codexis, Inc. | Production of fatty alcohols from engineered microorganisms |
| WO2014093070A1 (en) | 2012-12-14 | 2014-06-19 | Codexis, Inc. | Modified native beta-ketoacyl-acp synthases and engineered microorganisms |
| EP2935572B1 (en) | 2012-12-21 | 2020-09-30 | Codexis, Inc. | Engineered biocatalysts and methods for synthesizing chiral amines |
| WO2014113521A1 (en) | 2013-01-18 | 2014-07-24 | Codexis, Inc. | Engineered biocatalysts useful for carbapenem synthesis |
| CN115927231A (zh) | 2013-02-28 | 2023-04-07 | 科德克希思公司 | 用于工业生物催化的工程化转氨酶多肽 |
| EP2970927A4 (en) | 2013-03-15 | 2016-10-12 | Merck Sharp & Dohme | IMMOBILIZED KETOREDUCASTASES AND METHOD FOR THE PRODUCTION AND USE OF IMMOBILIZED KETOREDUCASTASES |
| KR101876172B1 (ko) * | 2013-04-17 | 2018-07-10 | 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 | 케톤의 거울상 이성질체 선택적 환원을 위한 디자이너 세포 및 거울상 이성질체 풍부한 알콜의 효율적인 생산에서의 이의 용도 |
| DK3068793T3 (da) | 2013-11-13 | 2021-03-22 | Codexis Inc | Manipulerede iminreductaser og fremgangsmåder til den reduktive aminering af keton- og aminforbindelser |
| US9133488B2 (en) | 2013-12-30 | 2015-09-15 | University Of Alaska Fairbanks | Synthetic methods and compounds related thereto |
| ES2686695T3 (es) | 2014-04-22 | 2018-10-19 | C-Lecta Gmbh | Cetorreductasas |
| WO2016130412A1 (en) | 2015-02-10 | 2016-08-18 | Codexis, Inc. | Ketoreductase polypeptides for the synthesis of chiral compounds |
| CN104659287B (zh) * | 2015-03-12 | 2017-05-31 | 京东方科技集团股份有限公司 | 像素界定层及制备方法、显示基板及制备方法、显示装置 |
| CA2983620A1 (en) | 2015-05-07 | 2016-11-10 | Codexis, Inc. | Penicillin-g acylases |
| CA3021009A1 (en) | 2016-05-05 | 2017-11-09 | Codexis, Inc. | Penicillin-g acylases |
| US10184117B2 (en) | 2016-06-09 | 2019-01-22 | Codexis, Inc. | Biocatalysts and methods for hydroxylation of chemical compounds |
| WO2017218325A1 (en) | 2016-06-15 | 2017-12-21 | Codexis, Inc. | Engineered beta-glucosidases and glucosylation methods |
| EP3515926B1 (en) | 2016-08-26 | 2023-10-25 | Codexis, Inc. | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds |
| US10745681B2 (en) | 2017-01-05 | 2020-08-18 | Codexis, Inc. | Penicillin-G acylases |
| SG11201906480QA (en) | 2017-02-03 | 2019-08-27 | Codexis Inc | Engineered glycosyltransferases and steviol glycoside glucosylation methods |
| US11021729B2 (en) | 2017-04-27 | 2021-06-01 | Codexis, Inc. | Ketoreductase polypeptides and polynucleotides |
| PL3635101T3 (pl) | 2017-05-08 | 2021-12-13 | Codexis, Inc. | Poddane inżynierii warianty ligazy |
| CA3064574A1 (en) | 2017-06-14 | 2018-12-20 | Codexis, Inc. | Engineered transaminase polypeptides for industrial biocatalysis |
| CN111051506B (zh) | 2017-06-27 | 2023-11-24 | 科德克希思公司 | 青霉素g酰化酶 |
| CN111417724A (zh) | 2017-06-30 | 2020-07-14 | 科德克希思公司 | T7 rna聚合酶变体 |
| CN111032863B (zh) | 2017-06-30 | 2024-10-22 | 科德克希思公司 | T7 rna聚合酶变体 |
| WO2019012095A1 (en) * | 2017-07-14 | 2019-01-17 | C-Lecta Gmbh | TCO-reductase |
| SG11202003094PA (en) | 2017-11-07 | 2020-05-28 | Codexis Inc | Transglutaminase variants |
| US11015180B2 (en) | 2017-12-13 | 2021-05-25 | Codexis, Inc. | Carboxyesterase polypeptides for amide coupling |
| ES3018269T3 (en) | 2017-12-13 | 2025-05-14 | Glaxosmithkline Ip Dev Ltd | Carboxyesterase biocatalysts |
| GB201802383D0 (en) * | 2018-02-14 | 2018-03-28 | Givaudan Sa | Process |
| ES2975412T3 (es) | 2018-06-21 | 2024-07-05 | Fis Fabbrica Italiana Sintetici Spa | Proceso enzimático para la preparación de droxidopa |
| WO2020014048A1 (en) | 2018-07-09 | 2020-01-16 | Codexis, Inc. | Engineered deoxyribose-phosphate aldolases |
| WO2020016749A2 (en) | 2018-07-16 | 2020-01-23 | Novartis Ag | Chemical process for preparing phenylpiperidinyl indole derivatives |
| EP3830106A4 (en) | 2018-07-30 | 2022-07-06 | Codexis, Inc. | MANIPULATED GLYCOSYLTRANSFERASES AND METHODS FOR STEVIOL GLYCOSIDE GLUCOSYLATION |
| US10961550B2 (en) | 2018-09-26 | 2021-03-30 | Kalamazoo Holdings, Inc. | Enzymatic process for production of modified hop products |
| CN113286876A (zh) * | 2018-10-26 | 2021-08-20 | T·巴尔 | 用于生物降解酒精的组合物和方法 |
| IL282456B2 (en) | 2018-10-29 | 2025-07-01 | Codexis Inc | Engineered dna polymerase variants |
| AU2019397401A1 (en) | 2018-12-14 | 2021-06-17 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| US12215359B2 (en) | 2019-05-01 | 2025-02-04 | Codexis, Inc. | Engineered glucose dehydrogenases and methods for the reductive amination of ketone and amine compounds |
| EP3963057A4 (en) | 2019-05-01 | 2023-06-14 | Codexis, Inc. | MANIPULATED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS |
| CA3142636A1 (en) | 2019-07-02 | 2021-01-07 | Codexis, Inc. | Engineered sucrose phosphorylase variant enzymes |
| EP4501403A3 (en) | 2019-08-30 | 2025-05-14 | Société des Produits Nestlé S.A. | Engineered lipase variants |
| CA3149870A1 (en) | 2019-09-12 | 2021-03-18 | Codexis, Inc. | Peroxidase activity towards 10-acetyl-3,7-dihydroxyphenoxazine |
| CN114729374B (zh) * | 2019-11-22 | 2024-12-17 | 株式会社Api | 羰基还原酶、编码该酶的核酸、以及利用它们的光学活性化合物的制造方法 |
| IL293038A (en) | 2019-11-26 | 2022-07-01 | Codexis Inc | Biocatalysts and methods for hydroxylation of chemical compounds |
| CA3168922A1 (en) | 2020-02-04 | 2021-08-12 | Codexis, Inc. | Engineered leucine decarboxylases |
| WO2021207200A2 (en) | 2020-04-10 | 2021-10-14 | Codexis, Inc. | Engineered transaminase polypeptides |
| US11959108B2 (en) | 2020-08-28 | 2024-04-16 | Codexis, Inc. | Engineered protease variants |
| KR20230145027A (ko) | 2020-08-28 | 2023-10-17 | 코덱시스, 인코포레이티드 | 조작된 아밀라제 변이체 |
| WO2022066155A1 (en) | 2020-09-24 | 2022-03-31 | Kalamazoo Holdings, Inc. | Enzymatic process for production of modified hop products |
| CN112410276B (zh) * | 2020-11-27 | 2023-03-21 | 江苏阿尔法药业股份有限公司 | 一种2-氯-1-(3,4-二氟苯基)乙酮还原酶重组菌株及构建方法和应用 |
| US11898174B2 (en) | 2020-12-18 | 2024-02-13 | Codexis, Inc. | Engineered uridine phosphorylase variant enzymes |
| US12110521B2 (en) | 2021-05-21 | 2024-10-08 | Syntis Bio, Inc. | Engineered methionine gamma lyase variants |
| CN117813376A (zh) * | 2021-08-13 | 2024-04-02 | 科德克希思公司 | 工程化核苷脱氧核糖基转移酶变体酶 |
| JP2024539636A (ja) | 2021-10-15 | 2024-10-29 | コデクシス， インコーポレイテッド | 操作されたｄｎａポリメラーゼバリアント |
| CA3265252A1 (en) | 2022-08-26 | 2024-02-29 | Tesaro Inc | BIOCATALYSTS AND ASSOCIATED PROCESSES |
| AR131406A1 (es) | 2022-12-20 | 2025-03-19 | Novartis Ag | Método de ligación de ácidos nucleicos |
| AR131405A1 (es) | 2022-12-20 | 2025-03-19 | Novartis Ag | Ligasas modificadas y usos de las mismas |
| WO2024150146A1 (en) | 2023-01-12 | 2024-07-18 | Novartis Ag | Engineered ketoreductase polypeptides |
| WO2025235589A1 (en) | 2024-05-08 | 2025-11-13 | Codexis, Inc. | Dna polymerase variants |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998035025A1 (en) * | 1997-02-07 | 1998-08-13 | Kaneka Corporation | Novel carbonyl reductase, gene that encodes the same, and method of utilizing these |
| WO1999023242A1 (en) * | 1997-11-04 | 1999-05-14 | Eli Lilly And Company | Ketoreductase gene and protein from yeast |
| WO2003004653A1 (en) * | 2001-07-02 | 2003-01-16 | Kaneka Corporation | Method of modifying enzyme and oxidoreductase variant |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9512837D0 (en) | 1995-06-23 | 1995-08-23 | Zeneca Ltd | reduction of ketone groups |
| US6531308B2 (en) * | 1997-11-04 | 2003-03-11 | Eli Lilly And Company | Ketoreductase gene and protein from yeast |
| DK1054860T3 (da) | 1997-12-19 | 2007-07-02 | Pfizer Ireland Pharmaceuticals | Proces for syntesen af 1,3-dioler |
| US6344569B1 (en) | 1998-04-30 | 2002-02-05 | Kaneka Corporation | Process for producing 6-cyanomethyl-1,3-dioxane-4-acetic acid derivatives |
| ATE375989T1 (de) | 1998-08-05 | 2007-11-15 | Kaneka Corp | Verfahren zur herstellung von 3,5-dihydroxy substituierten estern als zwischenprodukte zur herstellung optisch aktiver 2-(6-(hydroxymethyl)- 1,3-dioxan-4-yl)-essigsäure-derivate |
| CA2349181A1 (en) | 1998-11-12 | 2000-05-18 | Larry Kirn | Multi-reference, high-accuracy switching amplifier |
| WO2001004336A1 (de) | 1999-07-09 | 2001-01-18 | Forschungszentrum Jülich GmbH | Verfahren zur reduktion von keto-carbonsäuren und deren estern |
| HUP0105331A3 (en) | 1999-12-03 | 2005-10-28 | Kaneka Corp | Novel carbonyl reductase, gene thereof and method of using the same |
| US6492868B2 (en) | 2000-08-14 | 2002-12-10 | Larry Kirn | Dynamic range enhancement technique |
| DE60315958D1 (de) | 2002-03-18 | 2007-10-11 | Biocatalytics Inc | Alkohol-dehydrogenase mit hoher stabilität gegenüber lösungsmittel und temperatur |
| AU2003258187A1 (en) | 2002-08-09 | 2004-02-25 | Codexis, Inc. | Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives |
| BRPI0413498A (pt) * | 2003-08-11 | 2006-10-17 | Codexis Inc | método para produzir um éster de ácido carboxìlico substituìdo por hidróxi, ciano vicinal a partir de um éster de ácido carboxìlico substituìdo por hidróxi, halo vicinal, e, composição |
| DE102004029112B4 (de) | 2004-06-11 | 2007-06-21 | Julich Chiral Solutions Gmbh | Alkoholdehydrogenase zur stereoselektiven Gewinnung von Hydroxyverbindungen |
-
2004
- 2004-08-11 US US10/916,311 patent/US7629157B2/en active Active
- 2004-08-11 EP EP04781365A patent/EP1654354A1/en not_active Withdrawn
- 2004-08-11 JP JP2006523448A patent/JP2007502124A/ja active Pending
- 2004-08-11 CA CA002533838A patent/CA2533838A1/en not_active Abandoned
- 2004-08-11 WO PCT/US2004/026655 patent/WO2005017135A1/en not_active Ceased
-
2006
- 2006-01-17 IL IL173191A patent/IL173191A/en not_active IP Right Cessation
-
2009
- 2009-10-08 US US12/576,195 patent/US7833767B2/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998035025A1 (en) * | 1997-02-07 | 1998-08-13 | Kaneka Corporation | Novel carbonyl reductase, gene that encodes the same, and method of utilizing these |
| WO1999023242A1 (en) * | 1997-11-04 | 1999-05-14 | Eli Lilly And Company | Ketoreductase gene and protein from yeast |
| WO2003004653A1 (en) * | 2001-07-02 | 2003-01-16 | Kaneka Corporation | Method of modifying enzyme and oxidoreductase variant |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010539952A (ja) * | 2007-10-01 | 2010-12-24 | コデクシス， インコーポレイテッド | アゼチジノンの生産のためのケトレダクターゼポリペプチド |
| WO2011145211A1 (ja) * | 2010-05-21 | 2011-11-24 | 明治製菓株式会社 | ケトレダクターゼ変異体 |
| US8697409B2 (en) | 2010-05-21 | 2014-04-15 | Meiji Seika Pharma Co., Ltd. | Ketoreductase mutant |
| JP2022536500A (ja) * | 2019-06-13 | 2022-08-17 | アシムケム ラボラトリーズ （ティエンジン） カンパニー リミテッド | ケトレダクターゼ突然変異体及びキラルアルコールの生産方法 |
| JP7375052B2 (ja) | 2019-06-13 | 2023-11-07 | アシムケム ラボラトリーズ （ティエンジン） カンパニー リミテッド | ケトレダクターゼ突然変異体及びキラルアルコールの生産方法 |
| US12173345B2 (en) | 2019-06-13 | 2024-12-24 | Asymchem Laboratories (Tianjin) Co., Ltd. | Ketoreductase mutant and method for producing chiral alcohols |
Also Published As
| Publication number | Publication date |
|---|---|
| US20060195947A1 (en) | 2006-08-31 |
| IL173191A0 (en) | 2006-06-11 |
| IL173191A (en) | 2010-12-30 |
| CA2533838A1 (en) | 2005-02-24 |
| US7833767B2 (en) | 2010-11-16 |
| WO2005017135A1 (en) | 2005-02-24 |
| US20100028972A1 (en) | 2010-02-04 |
| EP1654354A1 (en) | 2006-05-10 |
| US7629157B2 (en) | 2009-12-08 |
| WO2005017135A8 (en) | 2012-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7629157B2 (en) | Ketoreductase polypeptides and related polynucleotides | |
| EP1660648B1 (en) | Improved glucose dehydrogenase polypeptides and related polynucleotides | |
| KR101502634B1 (ko) | 케토 환원 효소 및 이의 용도 | |
| CN114181877B (zh) | 一种合成香兰素的基因工程菌及其应用 | |
| US7790432B2 (en) | Alanine 2,3-aminomutases and related polynucleotides | |
| KR102093546B1 (ko) | 에탄올에서 아세토인의 생산방법 | |
| ES2437615T3 (es) | Producción de compuestos de carbonilo alfa-oxifuncionalizados | |
| WO2007028729A1 (en) | Nocardia globerula alcohol dehydrogenase and use thereof | |
| AU2021102284A4 (en) | Peptide linker, fusion protein comprising the peptide linker and uses thereof | |
| EP4551694A1 (en) | Ketoreductase enzymes for the synthesis of 1,3-diol substituted indanes | |
| JP2011205921A (ja) | ロドコッカス（Ｒｈｏｄｏｃｏｃｃｕｓ）属細菌組換体及びそれを用いた光学活性（Ｒ）−３−キヌクリジノールの製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070601 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070601 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100421 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100720 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100727 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100823 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101210 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110902 |